Product name: Thyroxine (T4) ### Registration number ANVISA: 10132590400 ### Hazard class: II ### Product code: 8744468 ## Trademark: IMMUNODIAGNOSTIC REAGENT KIT VITROS * ECi FOR TOTAL T4 ### Technical Name: # Batch numbers affected: 1845; 1880; 1900; 1930; 1950 의 안전성 경고

Agência Nacional de Vigilância Sanitária (ANVISA)에 따르면, 해당 안전성 경고 는 Brazil 에서 Johnson & Johnson do Brasil Ind. e Com. de Prod. para Saúde Ltda; ORTHO CLINICAL DIAGNOSTICS 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

안전성 경고는 의료기기 제품과 관련된 중요한 정보와 권고사항을 담고 있습니다. 물론 안전성 경고가 배포되었다고 해서 해당 제품이 무조건 안전하지 않은 제품이라는 것은 아닙니다. 보건의료업계 종사자와 의료기기 사용자들에게 배포되는 안전성 경고에는 회수(recall)도 포함될 수 있습니다. 제조사가 안전성 경고를 작성하기도 하지만, 보건당국에서 작성하는 경우도 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Safety alert
  • 사례 ID
    1976
  • 날짜
    2016-08-25
  • 사례 국가
  • 사례 출처
    ANVISA
  • 사례 출처 URL
  • 비고 / 경고
    Brazilian data is current through June 2018. All of the data comes from Anvisa, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Brazil.
  • 데이터 추가 비고
    Action required for laboratories that have the affected lot: • VITROS TT4 Reagent Kits (listed above and future lots 2008 and later) should only be used within 4 weeks of opening. Manually track the time interval for storing the reagent kits opened for Batches prior to 2008. • The VITROS TT4 Instructions for Use (IFU) will be updated to reflect this change. The revised Instructions for Use (IFU) will be available on our website at http://www.orthoclinical.com, when the next batch is released, which is expected to begin in June 2016. In the meantime, please keep this notification to checking the change in the storage requirement of open reagent kits. • In accordance with regulatory requirements, complete and return the Receipt Confirmation. • This is a situation in which the use of the product is not likely to cause adverse health consequences. • Incorrect value may cause undue results. The Laboratory Medical Officer should be consulted about any questions you may have regarding previously reported TT4 results to determine the appropriate course of action. The results of this or other diagnostic test should be used and interpreted only within the context of the general clinical picture. If you wish to notify technical complaints and adverse events use the following channels: Notivisa: Notices of adverse events (AE) and technical complaints (QT) for products subject to Sanitary Surveillance should be made through the NOTIVISA System. To access the System, you must register and select the Health Professional option, if you are a liberal professional or the Institution / Entity option, if you are a professional of an institution / entity. Technovigilance System: Patient or citizen can notify through the Technovigilance System / SISTEC access through the link
  • 원인
    This notification informs that the batches identified above have been approved and met the release test specifications prior to release. however, further testing indicated that the sample results, generated using the vitros tt4 reagent kits that were open more than 4 weeks ago, may demonstrate a negative bias.
  • 조치
    Field Action No. 16000094 triggered under the responsibility of Johnson & Johnson do Brasil Ind. And Com. De Prod. for Health Ltda.